Completeness of bladder cancer staging in the Danish Cancer Registry, 2004-2009

Clinical Epidemiology

Volumn 4, Issue SUPPL.2, 2012, Pages 25-31

  Holland Bill, Louise ^a   Frøslev, Trine ^a   Friis, Søren ^b   Olsen, Morten ^a   Harving, Niels ^c   Borre, Michael ^a   Søgaard, Mette ^a,c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bladder cancer; Cancer registry; Completeness; Denmark; TNM stage

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER INVASION; CANCER PATIENT; CANCER REGISTRY; CANCER STAGING; CHILD; CLASSIFICATION ALGORITHM; COMORBIDITY; DENMARK; FEMALE; GENDER; HUMAN; INFANT; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRESCHOOL CHILD; SCHOOL CHILD; TREND STUDY; TUMOR CLASSIFICATION;

EID: 84866636393     PISSN: None     EISSN: 11791349     Source Type: Journal    
DOI: 10.2147/CLEP.S31542     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-2917.
3. Danish Board of Health. Cancerregisteret 2009 [Cancer Registry 2009]. Copenhagen: Danish Board of Health; 2010. Danish. Available from: http://www.sst.dk/publ/Publ2010/DOKU/Registre/Cancerregisteret2009.pdf. Accessed November 23, 2011.
4. Greene F, Page D, Fleming I, et al. AJCC Cancer Staging Manual, 6th ed. New York: Springer-Verlag; 2002.
5. Youssef RF, Lotan Y. Predictors of outcome of non-muscle-invasive and muscle-invasive bladder cancer. Scientific World Journal. 2011;11:369-381.
6. Danish Board of Health. Kræftplan II [Cancer Plan II; web page on the Internet]. Copenhagen: Danish Board of Health; nd. Available at: http://www.sst.dk/Planlaegning%20og%20kvalitet/Kraeftbehandling/Nationale%20planer/Kraeftplan_II.aspx. Accessed November 28, 2011. Danish.
7. Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health. 2011;39(Suppl 7):42-45.
8. Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 2011;39(Suppl 7):22-25.
9. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry-history, content, quality and use. Dan Med Bull. 1997;44(5):535-539.
10. Danish Board of Health. Det moderniserede Cancerregister-metode og kvalitet [The Modernized Cancer Registry-Methodology and Quality]. Copenhagen: Danish Board of Health; 2009. Danish. Available at: http://www.sst.dk/-/media/Indberetning%20og%20statistik/Cancerregisteret/Metodebeskrivelse_publikation%20Cancerregisteret.ashx. Accessed April 25, 2012.
11. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39(Suppl 7):30-33.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
13. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol. 2011;11:83.
14. Lau EC, Mowat FS, Kelsh MA, et al. Use of electronic medical records (EMR) for oncology outcomes research: assessing the comparability of EMR information to patient registry and health claims data. Clin Epidemiol. 2011;3:259-272.
15. US National Cancer Institute. SEER Stat Fact Sheets: Bladder. Bethesda, MD: US National Cancer Institute; 2012. Available from: http://seer.cancer.gov/statfacts/html/urinb.html. Accessed January 6, 2012.
16. US National Cancer Institute. SEER registries [database on the Internet]. Bethesda, MD: US National Cancer Institute; nd. Available from: http://seer.cancer.gov/about/. Accessed January 6, 2012.
17. Yu JB, Gross CP, Wilson LD, Smith BD. NCI SEER public-use data: applications and limitations in oncology research. Oncology (Williston Park). 2009;23(3):288-295.
18. Merrill RM, Sloan A, Anderson AE, Ryker K. Unstaged cancer in the United States: a population-based study. BMC Cancer. 2011;11:402.
19. Koroukian SM, Xu F, Beaird H, Diaz M, Murray P, Rose JH. Complexity of care needs and unstaged cancer in elders: a population-based study. Cancer Detect Prev. 2007;31(3):199-206.
20. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55years and older. JAMA. 2001;285(7):885-892.
21. Havlik RJ, Yancik R, Long S, Ries L, Edwards B. The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer. 1994;74(Suppl 7):2101-2106.
22. Klassen AC, Curriero F, Kulldorff M, Alberg AJ, Platz EA, Neloms ST. Missing stage and grade in Maryland prostate cancer surveillance data, 1992-1997. Am J Prev Med. 2006;30(Suppl 2):S77-S87.
23. Lund L, Erichsen R, Norgaard M, Larsen EH, Borre M, Jacobsen J. Survival of invasive bladder cancer patients, 1998-2009; a central and northern Denmark population-based cohort study. Clin Epidemiol. 2011;3(Suppl 1):47-51.
24. Hermann GG, Horn T, Steven K. The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. J Urol. 1998;159(1):91-94.
25. Younes M, Sussman J, True LD. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer. 1990;66(3):543-548.
26. Bassi P, Ferrante GD, Piazza N, et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol. 1999;161(5):1494-1497.
27. Bella AJ, Stitt LW, Chin JL, Izawa JI. The prognostic significance of metastatic perivesical lymph nodes identified in radical cystectomy specimens for transitional cell carcinoma of the bladder. J Urol. 2003;170(6 Pt 1):2253-2257.
28. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006;176(6 Pt 1):2414-2422; Discussion 2422.
29. Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 1989;64(12):2448-2458.
30. Türkölmez K, Tokgöz H, Reşorlu B, Köse K, Bedük Y. Muscle-invasive bladder cancer: predictive factors and prognostic difference between primary and progressive tumors. Urology. 2007;70(3):477-481.